BTK and B-cell chronic lymphocytic leukemia: Although no results from head-to-head trials comparing acalabrutinib with ibrutinib or any other BTK inhibitor are available, a summary of the safety profile of each agent in MCL, CLL, and WM is presented in Table 1.